Shares of NextCure, Inc. (NASDAQ:NXTC – Get Rating) were up 3.3% during mid-day trading on Thursday . The company traded as high as $4.49 and last traded at $4.43. Approximately 108,372 shares traded hands during trading, a decline of 27% from the average daily volume of 148,640 shares. The stock had previously closed at $4.29.
Wall Street Analyst Weigh In
Separately, Piper Sandler reduced their price target on shares of NextCure from $21.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, May 23rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, NextCure has an average rating of “Moderate Buy” and an average price target of $15.00.
NextCure Trading Up 6.3 %
The company’s 50 day moving average price is $4.50 and its 200-day moving average price is $4.66.
Institutional Investors Weigh In On NextCure
Institutional investors have recently modified their holdings of the stock. Silverarc Capital Management LLC grew its position in shares of NextCure by 1.6% during the 1st quarter. Silverarc Capital Management LLC now owns 196,187 shares of the company’s stock valued at $953,000 after buying an additional 3,175 shares during the last quarter. DAFNA Capital Management LLC grew its position in shares of NextCure by 2.3% during the 4th quarter. DAFNA Capital Management LLC now owns 187,696 shares of the company’s stock valued at $1,126,000 after buying an additional 4,205 shares during the last quarter. State Street Corp grew its position in NextCure by 10.7% in the 1st quarter. State Street Corp now owns 57,092 shares of the company’s stock worth $277,000 after purchasing an additional 5,515 shares during the last quarter. UBS Group AG grew its position in NextCure by 224.6% in the 1st quarter. UBS Group AG now owns 9,160 shares of the company’s stock worth $45,000 after purchasing an additional 6,338 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in NextCure by 104.0% in the 1st quarter. JPMorgan Chase & Co. now owns 17,895 shares of the company’s stock worth $87,000 after purchasing an additional 9,121 shares during the last quarter. Institutional investors and hedge funds own 51.83% of the company’s stock.
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.
- Get a free copy of the StockNews.com research report on NextCure (NXTC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.